vs
Cellectis S.A.（CLLS）与Lakeside Holding Ltd（LSH）财务数据对比。点击上方公司名可切换其他公司
Cellectis S.A.的季度营收约是Lakeside Holding Ltd的1.4倍（$9.5M vs $7.0M），Lakeside Holding Ltd净利率更高（-22.6% vs -265.9%，领先243.3%），Cellectis S.A.同比增速更快（375.0% vs 95.0%）
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
CLLS vs LSH — 直观对比
营收规模更大
CLLS
是对方的1.4倍
$7.0M
营收增速更快
CLLS
高出279.9%
95.0%
净利率更高
LSH
高出243.3%
-265.9%
损益表 — Q2 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.5M | $7.0M |
| 净利润 | $-25.3M | $-1.6M |
| 毛利率 | — | 27.2% |
| 营业利润率 | -181.1% | -21.3% |
| 净利率 | -265.9% | -22.6% |
| 营收同比 | 375.0% | 95.0% |
| 净利润同比 | -51.9% | 18.7% |
| 每股收益（稀释后） | $-0.28 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLLSLSH
| Q4 25 | — | $7.0M | ||
| Q3 25 | — | $6.1M | ||
| Q2 25 | — | $6.3M | ||
| Q1 25 | — | $3.8M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | $9.5M | — | ||
| Q3 23 | $1.6M | — |
净利润CLLSLSH
| Q4 25 | — | $-1.6M | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | — | $-893.1K | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | — | $-1.3M | ||
| Q2 24 | $-25.3M | — | ||
| Q3 23 | $-17.5M | — |
毛利率CLLSLSH
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 18.2% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 18.8% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 12.8% | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — |
营业利润率CLLSLSH
| Q4 25 | — | -21.3% | ||
| Q3 25 | — | -20.8% | ||
| Q2 25 | — | -8.9% | ||
| Q1 25 | — | -28.2% | ||
| Q4 24 | — | -55.6% | ||
| Q3 24 | — | -32.5% | ||
| Q2 24 | -181.1% | — | ||
| Q3 23 | -1258.1% | — |
净利率CLLSLSH
| Q4 25 | — | -22.6% | ||
| Q3 25 | — | -22.2% | ||
| Q2 25 | — | -14.2% | ||
| Q1 25 | — | -28.2% | ||
| Q4 24 | — | -54.1% | ||
| Q3 24 | — | -32.7% | ||
| Q2 24 | -265.9% | — | ||
| Q3 23 | -1064.1% | — |
每股收益（稀释后）CLLSLSH
| Q4 25 | — | $-0.08 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $-0.14 | ||
| Q4 24 | — | $-0.26 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | $-0.28 | — | ||
| Q3 23 | $-0.31 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.0M | $1.6M |
| 总债务越低越好 | — | $2.4M |
| 股东权益账面价值 | $148.6M | $12.2M |
| 总资产 | $407.1M | $24.3M |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资CLLSLSH
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $4.5M | ||
| Q2 25 | — | $5.0M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $2.7M | ||
| Q2 24 | $149.0M | — | ||
| Q3 23 | — | — |
总债务CLLSLSH
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $774.2K | ||
| Q4 24 | — | $784.8K | ||
| Q3 24 | — | $589.9K | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — |
股东权益CLLSLSH
| Q4 25 | — | $12.2M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $2.8M | ||
| Q1 25 | — | $749.8K | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $3.6M | ||
| Q2 24 | $148.6M | — | ||
| Q3 23 | $76.1M | — |
总资产CLLSLSH
| Q4 25 | — | $24.3M | ||
| Q3 25 | — | $18.6M | ||
| Q2 25 | — | $14.4M | ||
| Q1 25 | — | $9.9M | ||
| Q4 24 | — | $9.8M | ||
| Q3 24 | — | $10.8M | ||
| Q2 24 | $407.1M | — | ||
| Q3 23 | $209.7M | — |
负债/权益比CLLSLSH
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $-453.5K |
| 自由现金流经营现金流 - 资本支出 | $27.6M | — |
| 自由现金流率自由现金流/营收 | 290.5% | — |
| 资本支出强度资本支出/营收 | 13.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CLLSLSH
| Q4 25 | — | $-453.5K | ||
| Q3 25 | — | $-4.0M | ||
| Q2 25 | — | $-483.7K | ||
| Q1 25 | — | $-238.3K | ||
| Q4 24 | — | $-530.2K | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | $28.9M | — | ||
| Q3 23 | — | — |
自由现金流CLLSLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-497.4K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-560.5K | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | $27.6M | — | ||
| Q3 23 | — | — |
自由现金流率CLLSLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -15.6% | ||
| Q3 24 | — | -34.5% | ||
| Q2 24 | 290.5% | — | ||
| Q3 23 | — | — |
资本支出强度CLLSLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | 13.2% | — | ||
| Q3 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLLS
暂无分部数据
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
